Navigation Links
Ambit Biosciences Announces Second Quarter 2014 Operating Results
Date:8/12/2014

SAN DIEGO, Aug. 12, 2014 /PRNewswire/ -- Ambit Biosciences (NASDAQ: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced operating results for the second quarter 2014.  The company will host a conference call today to discuss financial results for the quarter and to provide an operational update for the first half of 2014.

"We are pleased to have initiated our QUANTUM-R Phase 3 trial, our most notable achievement of the first half," said Michael Martino, Ambit's President and Chief Executive Officer.  "The trial is progressing and sites continue to be activated on plan.  This will remain our primary operating focus throughout the year.  We are also pleased with the progress in multiple investigator- and company-sponsored studies that continue to suggest that quizartinib may be a workhorse in the broader fight against AML in newly diagnosed patients and as a maintenance therapy in patients after transplant.  With QUANTUM-R underway, we are taking the next steps to execute this broader vision for quizartinib."

The Company announced the initiation of the Phase 3 QUANTUM-R registrational clinical trial in April of 2014.  This trial compares quizartinib as monotherapy to chemotherapy regimens for relapsed/refractory acute myeloid leukemia (AML) patients with the FMS-like tyrosine kinase-3 (FLT3)-ITD mutation.  Site initiation and patient enrollment are ongoing, with a planned total enrollment of 326 patients in the United States, Western Europe, Canada and Australia.

At June 30, 2014, the Company had cash and equivalents of $52.8 million, compared to $71.2 million at December 31, 2013.  The decrease of $18.4 million in the first half of 2014 was primarily due to the use of cash to fund operations.

The
'/>"/>

SOURCE Ambit Biosciences
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Ambit Biosciences To Announce Second Quarter 2014 Financial Results
2. Ambit Announces Presentations At The 55th Annual Meeting Of The American Society Of Hematology (ASH)
3. Ambit Announces Participation At Oppenheimer 24th Annual Healthcare Conference
4. Ambit Biosciences Provides Regulatory Update Following FDA Meeting Regarding Quizartinib (AC220)
5. Ambit Biosciences to Announce Third Quarter 2013 Financial and Operating Results and Conference Call
6. Ambit Biosciences Corporation Announces Second Quarter 2013 Operational Results
7. Ambit Biosciences to Announce Second Quarter 2013 Operational Results and Conference Call
8. Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology
9. Lo studio pubblicato su European Radiology esalta ulteriormente lutilizzo della tomosintesi al seno di Hologic nellambito dello screening del cancro con utilizzo della doppia lettura
10. Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
11. Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 18, 2014 Capnia, Inc. (NASDAQ: ... medical diagnostics based on its proprietary Sensalyze™ Technology ... announced financial results for the third quarter and ... "Following the completion of our initial public offering ... the recently initiated CoSense® commercial launch," said Anish ...
(Date:12/19/2014)... LYON, France , Dec. 19, 2014 /PRNewswire/ ... and Adocia (Euronext Paris: FR0011184241 – ADOC) today announced ... insulin, known as BioChaperone Lispro, for treatment in people ... relies on Adocia,s proprietary BioChaperone® technology and is currently ... will develop BioChaperone Lispro with the goal of optimizing ...
(Date:12/17/2014)... Dec. 17, 2014  Strategic Health Services, Inc. (SHS), ... today announced a strategic agreement with QualCare, Inc., a leading ... Jersey regional marketplace.  This agreement will further ... and wellness solutions QualCare brings to its clients in ... region. QualCare plans cover more than ...
Breaking Medicine Technology:Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 3
... Today is an exciting day for men with advanced prostate ... affected. Today a new prostate cancer treatment option, Provenge, was approved by ... , , ... innovative treatment option made available for patients with asymptomatic or minimally symptomatic ...
... Dendreon Corporation (Nasdaq: DNDN ) ... Administration (FDA) has approved PROVENGE® (sipuleucel-T), an autologous ... minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer (CRPC). ... against prostatic acid phosphatase (PAP), an antigen expressed ...
Cached Medicine Technology:Advanced Prostate Cancer Patients Finally Have Another Option 2FDA Approves PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer 2FDA Approves PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer 3FDA Approves PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer 4FDA Approves PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer 5FDA Approves PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer 6FDA Approves PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer 7
(Date:12/20/2014)... York (PRWEB) December 20, 2014 ... to move forward in U.S. courts, Bernstein Liebhard ... which suggests that children treated with the medication ... linked to breast development and lactation. The study, ... 34 children and adolescents who began treatment with ...
(Date:12/20/2014)... Developers of FCPX 3rd ... plugin for Final Cut Pro X entitled TranSlice Volume ... allows users to create hand drawn text animations without ... CEO of Pixel Film Studios. “TranSlice Volume 5 was ... an easy to use interface.” , TranSlice Volume 5 ...
(Date:12/20/2014)... December 20, 2014 Today, Balfleet.com, one ... a Christmas Sale, offering 50%-70% off on its ... season. , The mother of the bride dresses from ... company is 24/7 accessible and takes pride in providing ... , “We are offering great discounts on our mother ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Sub Zero Ice ... sponsor a blood drive Sunday the 28th from 2pm-6pm at ... & Sawyer Road in Sarasota, FL. , Inquiries regarding time ... you for participating in the donating process, Sub Zero Ice ... flash frozen, custom ice cream. , About Sub Zero Ice ...
(Date:12/19/2014)... December 19, 2014 SuperCloset raises the ... Rooms. SuperCloset continues to offer indoor growers the most ... of the new SuperClone Rooms with the award winning ... turnkey indoor hydroponic grow room setup. , The SuperClone ... SuperCloset’s SuperPonic SuperCloner 50 . The ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2Health News:Balfleet.com is Offering 50%-70% Off of its Mother of the Bride Dresses 2Health News:Shark Tank’s Sub Zero Ice Cream Sponsors Blood Drive 2Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2
... and Eons.com founder Jeff Taylor and,futurist Leanne Kaiser ... SAN DIEGO, Oct. 9 The following ... Washington, D.C.-based independent accreditor that,offers more than 20 ... Currently URAC accredits more than 400 health care,management ...
... a multicenter study led by Johns Hopkins Children,s Center ... hydrocortisone, a steroid believed to fight inflammation and prevent ... little or no benefit and that low cortisol levels ... the other hand, appeared to increase the risk of ...
... in early 2009 -, CORONA, Calif., Oct. ... a leading specialty pharmaceutical,company, announced today that the ... (silodosin), the company,s new alpha blocker for,the treatment ... BPH is the number one reason patients visit ...
... 8 Continuing its efforts to,educate, inform and ... a,not-for-profit patient-focused organization, is hosting its 25-minute live,call-in ... on,Monday, October 13, 2008 at 6:00 PM on ... in-depth discussion of women,s health,with Deborah Edberg, MD, ...
... Online Press Registration Closes Next Friday, WASHINGTON, ... meet in San Diego, Calif., Oct. 25-29, to ... American Public Health,Association,s (APHA) 136th Annual Meeting., ... presenting the latest public health science at nearly ...
... production in the newly diagnosed. , , WEDNESDAY, Oct. 8 ... that may change the way the immune system responds ... diabetes. , "By a very simple vaccination, without adverse ... insulin secretion, which may be extremely important for diabetic ...
Cached Medicine News:Health News:Health Care Management Thought Leaders Converge for Summit on Cost, Quality and Consumer Focus 2Health News:Steroid treatment offers no benefit in preemies, Hopkins Children's study suggests 2Health News:Steroid treatment offers no benefit in preemies, Hopkins Children's study suggests 3Health News:Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH) 2Health News:Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH) 3Health News:Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH) 4Health News:Women's Health - An Intimate Discussion 2Health News:Thousands of Public Health Experts to Address Leading Issues at APHA Annual Meeting, Oct. 25-29 2Health News:New Vaccine May Help Type 1 Diabetics in Future 2Health News:New Vaccine May Help Type 1 Diabetics in Future 3
... a mesh plug to treat large or ... hernias and femoralhernias. The self-expanding plug perfectly ... completely. Premilene Mesh Self-Forming Plug is a ... Mesh. The plug corresponds with all properties ...
... Lightweight and ergonomically designed with a 10-foot, ... Megadyne's E-Z PEN reusable electrosurgical pencils are ... the patented E-Z CLEAN non-stick tips allowing ... faster. The E-Z CLEAN PTFE coating ...
... Applied Fiberoptics Gemini surgical headlight is perfectly ... is durable and ultra-low-profile and illuminates brilliantly ... the annoying "rams effect." The fully adjustable ... designed to sit low on the brow, ...
... ... , ... MC-3 with Multiport - A three-lamp lightsource , it ... reserved for backup. Designed with managed care in mind, it includes universal turrets to accept most ...
Medicine Products: